

Markus P Radsak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4306801/publications.pdf>

Version: 2024-02-01

127
papers

5,567
citations

116194

36
h-index

97045

71
g-index

135
all docs

135
docs citations

135
times ranked

10138
citing authors

#	ARTICLE	IF	CITATIONS
1	CD27 expression on Treg cells limits immune responses against tumors. <i>Journal of Molecular Medicine</i> , 2022, 100, 439-449.	1.7	23
2	Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. <i>ACS Nano</i> , 2022, 16, 4426-4443.	7.3	33
3	Physical activity specifically evokes release of cell-free DNA from granulocytes thereby affecting liquid biopsy. <i>Clinical Epigenetics</i> , 2022, 14, 29.	1.8	21
4	Hypermethylation of intron 2 in childhood cancer patients, leukemia and tumor cell lines suggest a role for oncogenic transformation.. <i>EXCLI Journal</i> , 2022, 21, 117-143.	0.5	1
5	Lipid presentation by the protein C receptor links coagulation with autoimmunity. <i>Science</i> , 2021, 371, .	6.0	66
6	Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. <i>Leukemia Research</i> , 2021, 110, 106646.	0.4	2
7	Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry. <i>Blood</i> , 2021, 138, 1130-1130.	0.6	0
8	Genomic Landscape and Molecular Risk in Patients with Advanced Myelofibrosis Treated within the Multicenter Phase Ib/II MPNSG0212 (POMINC) Trial. <i>Blood</i> , 2021, 138, 4637-4637.	0.6	0
9	Neutrophil extracellular traps impair fungal clearance in a mouse model of invasive pulmonary aspergillosis. <i>Immunobiology</i> , 2020, 225, 151867.	0.8	28
10	Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA. <i>Cells</i> , 2020, 9, 2034.	1.8	57
11	MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S319-S320.	0.2	1
12	Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery. <i>Frontiers in Immunology</i> , 2020, 11, 266.	2.2	33
13	ERK3/MAPK6 controls IL-8 production and chemotaxis. <i>ELife</i> , 2020, 9, .	2.8	25
14	Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. <i>European Journal of Immunology</i> , 2019, 49, 2083-2094.	1.6	8
15	Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results. <i>Annals of Oncology</i> , 2019, 30, vi81.	0.6	2
16	Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) " Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S221-S222.	0.2	2
17	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	5.1	330
18	Antifungal Drugs Influence Neutrophil Effector Functions. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8

#	ARTICLE	IF	CITATIONS
19	CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. <i>Frontiers in Immunology</i> , 2019, 10, 123.	2.2	28
20	Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. <i>Scientific Reports</i> , 2019, 9, 19911.	1.6	20
21	Dermal CD207-Negative Migratory Dendritic Cells Are Fully Competent to Prime Protective, Skin Homing Cytotoxic T-Lymphocyte Responses. <i>Journal of Investigative Dermatology</i> , 2019, 139, 422-429.	0.3	9
22	Investigation of charge ratio variation in mRNA â€œ DEAE-dextran polyplex delivery systems. <i>Biomaterials</i> , 2019, 192, 612-620.	5.7	40
23	Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia. <i>Blood</i> , 2019, 134, 672-672.	0.6	11
24	Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. <i>Leukemia</i> , 2018, 32, 1762-1767.	3.3	27
25	Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses. <i>Scientific Reports</i> , 2018, 8, 5558.	1.6	16
26	HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes. <i>Blood Advances</i> , 2018, 2, 3137-3148.	2.5	31
27	Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer. <i>Scientific Reports</i> , 2018, 8, 10766.	1.6	15
28	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemiaâ€”results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
29	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
30	Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7018-7018.	0.8	0
31	CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. <i>Blood</i> , 2018, 132, 3690-3690.	0.6	0
32	The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation. <i>Haematologica</i> , 2017, 102, e191-e194.	1.7	38
33	Human NACHT, LRR, and PYD domainâ€œcontaining protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1054-1067.e10.	1.5	105
34	Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5â€œazacitidine. <i>European Journal of Haematology</i> , 2017, 99, 112-118.	1.1	13
35	Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 2095-2101.	0.8	16
36	Neuroendocrine Modulation of IL-27 in Macrophages. <i>Journal of Immunology</i> , 2017, 199, 2503-2514.	0.4	20

#	ARTICLE	IF	CITATIONS
37	Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. <i>Lancet Oncology</i> , The, 2017, 18, 1338-1347.	5.1	241
38	ADAMTS-13 regulates neutrophil recruitment in a mouse model of invasive pulmonary aspergillosis. <i>Scientific Reports</i> , 2017, 7, 7184.	1.6	10
39	9-Phenanthrol enhances the generation of an CD8 + T cell response following transcutaneous immunization with imiquimod in mice. <i>Journal of Dermatological Science</i> , 2017, 87, 260-267.	1.0	5
40	Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization. <i>Journal of Dermatological Science</i> , 2017, 87, 300-306.	1.0	10
41	Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. <i>Journal of Dermatological Science</i> , 2017, 87, 252-259.	1.0	22
42	Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1454.	2.2	201
43	Influence of exercise training on proangiogenic Tie-2 monocytes and circulating angiogenic cells in patients with peripheral arterial disease. <i>Clinical Research in Cardiology</i> , 2016, 105, 666-676.	1.5	19
44	Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. <i>Oncology Letters</i> , 2016, 12, 1257-1264.	0.8	10
45	Leukocyte "platelet aggregates" a phenotypic characterization of different stages of peripheral arterial disease. <i>Platelets</i> , 2016, 27, 658-667.	1.1	17
46	Phenotypic and functional characterization of neutrophils and monocytes from patients with myelodysplastic syndrome by flow cytometry. <i>Cellular Immunology</i> , 2016, 308, 19-26.	1.4	11
47	Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization. <i>Cellular Immunology</i> , 2016, 308, 35-43.	1.4	16
48	The skin as an orchestrator of influenza immunity. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 139-140.	4.6	3
49	Inflammation is associated with a reduced number of pro-angiogenic Tie-2 monocytes and endothelial progenitor cells in patients with critical limb ischemia. <i>Angiogenesis</i> , 2016, 19, 67-78.	3.7	18
50	Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. <i>Blood</i> , 2016, 128, 3168-3168.	0.6	9
51	Luspatercept Response in ESA-Na ⁺ /RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 5551-5551.	0.6	0
52	The Impact of NFAT Inhibition on Neutrophil Effector Functions in Patients after Allogeneic Hematopoietic Stem Cell Transplantation and on Neutrophil Antifungal Defense and Myelopoiesis in Cyclosporin f Treated and NFATc1LysM Mice. <i>Blood</i> , 2016, 128, 3679-3679.	0.6	0
53	Idelalisib Impairs TREM-1 and TLR Mediated Neutrophil Activation. <i>Blood</i> , 2016, 128, 2510-2510.	0.6	2
54	Ibrutinib Abrogates TREM-1 Mediated Neutrophil Activation. <i>Blood</i> , 2016, 128, 3691-3691.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. <i>Blood</i> , 2016, 128, 2815-2815.	0.6	1
56	Evaluation and Validation of the Detection of soluble Triggering Receptor Expressed on Myeloid Cells 1 by Enzyme-linked immunosorbent Assay. <i>Scientific Reports</i> , 2015, 5, 15381.	1.6	8
57	Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1071-1083.	1.8	54
58	Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury. <i>PLoS Pathogens</i> , 2015, 11, e1004651.	2.1	532
59	285 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF NEUTROPHILS AND MONOCYTES FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME BY FLOW CYTOMETRY. <i>Leukemia Research</i> , 2015, 39, S142.	0.4	0
60	Change of walking distance in intermittent claudication: impact on inflammation, oxidative stress and mononuclear cells: a pilot study. <i>Clinical Research in Cardiology</i> , 2015, 104, 751-763.	1.5	21
61	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
62	Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. <i>Blood</i> , 2015, 126, 2862-2862.	0.6	4
63	Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. <i>Blood</i> , 2015, 126, 92-92.	0.6	18
64	Combined Immunotherapy Against Cancer: Limited Efficacy of Transcutaneous Immunization and Low-dose Cyclophosphamide. <i>Cancer and Oncology Research</i> , 2015, 3, 1-9.	0.2	0
65	Transcutaneous Immunization with a Solid Nanoscopic Imiquimod Suspension Enhances Tumor Rejection. <i>Blood</i> , 2015, 126, 2224-2224.	0.6	0
66	Neutrophil Recruitment Is Regulated By Adamts-13 in a Murine Model of Invasive Aspergillosis. <i>Blood</i> , 2015, 126, 1010-1010.	0.6	0
67	The Impact of NFAT Inhibition on Neutrophil Antifungal Defense and Myelopoiesis in Cyclosporine A Treated and NFATc1LysM Mice. <i>Blood</i> , 2015, 126, 1007-1007.	0.6	0
68	Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. <i>Exercise Immunology Review</i> , 2015, 21, 164-73.	0.4	69
69	Interruption of Macrophage-Derived IL-27(p28) Production by IL-10 during Sepsis Requires STAT3 but Not SOCS3. <i>Journal of Immunology</i> , 2014, 193, 5668-5677.	0.4	42
70	Distinct Signaling Cascades of TREM-1, TLR and NLR in Neutrophils and Monocytic Cells. <i>Journal of Innate Immunity</i> , 2014, 6, 339-352.	1.8	25
71	Oxidative burst and neutrophil elastase contribute to clearance of <i>Aspergillus fumigatus</i> pneumonia in mice. <i>Immunobiology</i> , 2014, 219, 87-96.	0.8	27
72	Donor and host B cell-derived IL-10 contributes to suppression of graft-versus-host disease. <i>European Journal of Immunology</i> , 2014, 44, 1857-1865.	1.6	41

#	ARTICLE	IF	CITATIONS
73	Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2658-2668.	1.1	196
74	Granulocyte functions are independent of arginine availability. <i>Journal of Leukocyte Biology</i> , 2014, 96, 1047-1053.	1.5	16
75	Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1696-1704.	2.0	21
76	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. <i>Blood</i> , 2014, 124, 12-12.	0.6	5
77	ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 411-411.	0.6	12
78	Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation. <i>PLoS ONE</i> , 2014, 9, e102664.	1.1	37
79	Effects of Regulatory T Cell–Dendritic Cell Interactions on Adaptive Immune Responses. , 2014, , 21-27.		0
80	Abstract 11888: MyD88 Expressed by Myeloid Cells is Essential for Angiotensin II-Induced Vascular Dysfunction, Inflammation and Arterial Hypertension. <i>Circulation</i> , 2014, 130, .	1.6	1
81	Bone Marrow Derived Mesenchymal Cells Secrete Granulopoietic Cytokines upon Danger Signaling. <i>Blood</i> , 2014, 124, 4115-4115.	0.6	0
82	A Role for NFAT in Innate Immunity: Neutrophil Effector Functions in Patients after Allogeneic Hematopoietic Stem Cell Transplantation Under Cyclosporine Ħ Treatment. <i>Blood</i> , 2014, 124, 2495-2495.	0.6	0
83	ADAMTS13 Regulates Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. <i>Blood</i> , 2014, 124, 4109-4109.	0.6	0
84	Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils. <i>Atherosclerosis</i> , 2013, 229, 396-403.	0.4	48
85	Mast Cell–deficient <i>Kit^{W-sh}</i> –Sash–Mutant Mice Display Aberrant Myelopoiesis Leading to the Accumulation of Splenocytes That Act as Myeloid-Derived Suppressor Cells. <i>Journal of Immunology</i> , 2013, 190, 5534-5544.	0.4	36
86	Mast cell-derived mediators promote murine neutrophil effector functions. <i>International Immunology</i> , 2013, 25, 553-561.	1.8	22
87	Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. <i>Blood</i> , 2013, 121, 723-733.	0.6	95
88	Patients with peripheral arterial disease show an ameliorated proinflammatory status over 12 months non-supervised exercise training parallel to an increased walking distance. <i>European Heart Journal</i> , 2013, 34, P5819-P5819.	1.0	0
89	Mechanisms of Cyclic Nucleotide Phosphodiesterases in Modulating T Cell Responses in Murine Graft-versus-Host Disease. <i>PLoS ONE</i> , 2013, 8, e58110.	1.1	15
90	Host and Donor B Cell-Derived IL-10 Ameliorates Murine Graft-Versus-Host Disease. <i>Blood</i> , 2013, 122, 4468-4468.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Levels of Soluble Triggering Receptor Expressed on Myeloid Cells 1 in Infectious Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2012, 83, 133-139.	1.2	14
92	Current insights into neutrophil homeostasis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1266, 171-178.	1.8	54
93	Multifunctional superparamagnetic MnO@SiO ₂ core/shell nanoparticles and their application for optical and magnetic resonance imaging. <i>Journal of Materials Chemistry</i> , 2012, 22, 9253.	6.7	59
94	Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 913-923.	0.6	28
95	A Role for Toll-Like Receptor Mediated Signals in Neutrophils in the Pathogenesis of the Anti-Phospholipid Syndrome. <i>PLoS ONE</i> , 2012, 7, e42176.	1.1	39
96	Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1198-1207.	1.8	34
97	Comparative transcutaneous immunization with imiquimod-containing ointments and potential of <i>in vitro</i> methods to predict effects. <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 218-228.	1.1	5
98	A New Algorithm and Panel Construction for Pediatric Leukemia Immunophenotyping Using 10-Color Flow Cytometry. <i>Blood</i> , 2012, 120, 4799-4799.	0.6	0
99	Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. <i>Blood</i> , 2011, 118, 2322-2332.	0.6	96
100	UV Exposure Boosts Transcutaneous Immunization and Improves Tumor Immunity: Cytotoxic T-Cell Priming through the Skin. <i>Journal of Investigative Dermatology</i> , 2011, 131, 211-219.	0.3	24
101	Genetic Variation Determines Mast Cell Functions in Experimental Asthma. <i>Journal of Immunology</i> , 2011, 186, 7225-7231.	0.4	37
102	Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization. <i>PLoS ONE</i> , 2011, 6, e27911.	1.1	16
103	New strategies for the manipulation of adaptive immune responses. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1443-1448.	2.0	17
104	Cyclic adenosine monophosphate and IL-10 coordinately contribute to nTreg cell-mediated suppression of dendritic cell activation. <i>Cellular Immunology</i> , 2010, 265, 91-96.	1.4	42
105	Impaired Mast Cell-Driven Immune Responses in Mice Lacking the Transcription Factor NFATc2. <i>Journal of Immunology</i> , 2009, 182, 6136-6142.	0.4	12
106	Signaling Pathways of the TREM-1- and TLR4-Mediated Neutrophil Oxidative Burst. <i>Journal of Innate Immunity</i> , 2009, 1, 582-591.	1.8	32
107	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. <i>Blood</i> , 2008, 111, 5610-5620.	0.6	258
108	Cancer immunoeediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. <i>FASEB Journal</i> , 2007, 21, 2442-2454.	0.2	90

#	ARTICLE	IF	CITATIONS
109	Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease. <i>Clinical and Developmental Immunology</i> , 2007, 2007, 1-7.	3.3	60
110	A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. <i>Blood</i> , 2007, 109, 2985-2988.	0.6	45
111	TREM-1 ligand expression on platelets enhances neutrophil activation. <i>Blood</i> , 2007, 110, 1029-1035.	0.6	179
112	Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 57-65.	2.9	26
113	Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. <i>Clinical Reviews in Allergy and Immunology</i> , 2007, 32, 57-65.	2.9	1
114	Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. <i>Blood</i> , 2006, 108, 544-550.	0.6	218
115	Herpes virus entry mediator synergizes with Toll-like receptor mediated neutrophil inflammatory responses. <i>Immunology</i> , 2006, 119, 404-411.	2.0	13
116	Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. <i>European Journal of Immunology</i> , 2006, 36, 2613-2623.	1.6	9
117	Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5042-5047.	3.3	41
118	Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Gp96 Amplifies Innate and Adaptive Immune Responses. <i>Journal of Biological Chemistry</i> , 2006, 281, 22545-22553.	1.6	119
119	Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. <i>European Journal of Immunology</i> , 2005, 35, 1557-1566.	1.6	183
120	Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod. <i>Journal of Immunology</i> , 2005, 174, 2476-2480.	0.4	162
121	Triggering Receptor Expressed on Myeloid Cells-1 in Neutrophil Inflammatory Responses: Differential Regulation of Activation and Survival. <i>Journal of Immunology</i> , 2004, 172, 4956-4963.	0.4	186
122	<i>Aspergillus fumigatus</i> antigens activate innate immune cells via toll-like receptors 2 and 4. <i>British Journal of Haematology</i> , 2004, 125, 392-399.	1.2	156
123	T cell avidity determines the level of CTL activation. <i>European Journal of Immunology</i> , 2004, 34, 1798-1806.	1.6	26
124	The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. <i>Blood</i> , 2003, 101, 2810-2815.	0.6	70
125	Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells. <i>Kidney International</i> , 2001, 60, 2247-2262.	2.6	85
126	Expression of major histocompatibility class II antigens on polymorphonuclear neutrophils in patients with Wegener's granulomatosis. <i>Kidney International</i> , 1999, 55, 1811-1818.	2.6	36

#	ARTICLE	IF	CITATIONS
127	Neutrophil-Specific Knockdown of β 2 Integrins Impairs Antifungal Effector Functions and Aggravates the Course of Invasive Pulmonal Aspergillosis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4